Rethinking clinical delivery of adult stem cell therapies
In this thoughtful commentary, Octane leaders and scientists Tim Smith, Alexis Pietak and Nuala Trainor discuss how major challenges in the Good Manufacturing Practice (GMP) production of clinically significant numbers of autologous adult stem cells can be addressed by automated cell culture “GMP-in-a-box” systems. Such an approach may result in a distributed, decentralized model where personalized cell therapies are produced at point-of-care in primary care facilities.
Nature Biotechnology, 32, 729–735 (2014)
Authors: Nuala Trainor, Alexis Pietak and Tim Smith
We’re advancing personalized cell therapy as the standard of care through a partnership between Octane Biotech and the Lonza Group